SAB Biotherapeutics (SABS) Construction in Progress (2021 - 2023)

SAB Biotherapeutics (SABS) has 3 years of Construction in Progress data on file, last reported at $329617.0 in Q1 2023.

• Quarterly Construction in Progress changed N/A year-over-year to $329617.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $329617.0 (changed N/A YoY) and the FY2022 annual result came in at $137811.0, down 35.47% from the prior year.
• Construction in Progress rose to $329617.0 in Q1 2023, from $137811.0 in the prior quarter.
• In the past five years, Construction in Progress ranged from a high of $329617.0 in Q1 2023 to a low of $137811.0 in Q4 2022.
• A 3-year average of $226997.3 and a median of $213564.0 in 2021 frame the typical range for Construction in Progress.
• The widest YoY moves for Construction in Progress: up 35.47% in 2022, down 35.47% in 2022.
• Tracing SABS's Construction in Progress over 3 years: stood at $213564.0 in 2021, then plunged by 35.47% to $137811.0 in 2022, then surged by 139.18% to $329617.0 in 2023.
• The last three Construction in Progress figures came in at $329617.0 (Q1 2023), $137811.0 (Q4 2022), and $213564.0 (Q4 2021), per Business Quant data.